Lasofoxifene Information & Lasofoxifene Links at HealthHaven.com

Lasofoxifene
Systematic (IUPAC) name
	(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
Identifiers
CAS number	180916-16-9
ATC code	G03XC
PubChem	216416
Chemical data
Formula	C28H31NO2
Mol. mass	413.55 g/mol; 563.64 g/mol (tartrate)
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy^[1], and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).

In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.

On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.

[edit] References

^ Gennari L, Merlotti D, Martini G, Nuti R (2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opin Investig Drugs 15 (9): 1091–103. doi:10.1517/13543784.15.9.1091. PMID 16916275.

[edit] External links

"Reference site for lasofoxifene information". Anakena Internet Services SL. http://www.lasofoxifene.com/. Retrieved 2008-03-18.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[pmid16916275-0] Gennari L, Merlotti D, Martini G, Nuti R (2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opin Investig Drugs 15 (9): 1091–103. doi:10.1517/13543784.15.9.1091. PMID 16916275.

[1]